Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41


Use of biomarkers in clinical trials of Alzheimer disease: from concept to application.

Wu L, Rosa-Neto P, Gauthier S.

Mol Diagn Ther. 2011 Dec 1;15(6):313-25. doi: 10.2165/11595090-000000000-00000.


The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2. Review.


Longitudinal patterns of β-amyloid deposition in nondemented older adults.

Sojkova J, Zhou Y, An Y, Kraut MA, Ferrucci L, Wong DF, Resnick SM.

Arch Neurol. 2011 May;68(5):644-9. doi: 10.1001/archneurol.2011.77.


Alzheimer's disease.

Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E.

Lancet. 2011 Mar 19;377(9770):1019-31. doi: 10.1016/S0140-6736(10)61349-9. Epub 2011 Mar 1. Review.


Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Någren K, Helin S, Parkkola R, Viitanen M, Rinne JO.

Neurology. 2011 Mar 22;76(12):1085-90. doi: 10.1212/WNL.0b013e318212015e. Epub 2011 Feb 16.


Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.

Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2011 Mar;7(2):133-41. doi: 10.1016/j.jalz.2010.08.230. Epub 2011 Feb 1.


Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC.

Ann Neurol. 2011 Jan;69(1):181-92. doi: 10.1002/ana.22248.


Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

Herholz K.

Expert Rev Neurother. 2010 Nov;10(11):1667-73. doi: 10.1586/ern.10.136. Review.


Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.


Comparing predictors of conversion and decline in mild cognitive impairment.

Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2010 Jul 20;75(3):230-8. doi: 10.1212/WNL.0b013e3181e8e8b8. Epub 2010 Jun 30.


Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5.

Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A.

Neuron. 2010 Jun 10;66(5):739-54. doi: 10.1016/j.neuron.2010.04.029.


Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.

Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR Jr, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):239-46. doi: 10.1016/j.jalz.2010.03.006. Review.


The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):202-11.e7. doi: 10.1016/j.jalz.2010.03.007. Review.


Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.

Devanand DP, Mikhno A, Pelton GH, Cuasay K, Pradhaban G, Dileep Kumar JS, Upton N, Lai R, Gunn RN, Libri V, Liu X, van Heertum R, Mann JJ, Parsey RV.

J Geriatr Psychiatry Neurol. 2010 Sep;23(3):185-98. doi: 10.1177/0891988710363715. Epub 2010 Apr 29.


Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.

Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C, Martins RN, O'Keefe GJ, Salvado O, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Research Group.

Ann Neurol. 2010 Mar;67(3):317-24. doi: 10.1002/ana.21955.


The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.

Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD.

PLoS One. 2010 Mar 3;5(3):e9505. doi: 10.1371/journal.pone.0009505.


Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative.

Chen K, Langbaum JB, Fleisher AS, Ayutyanont N, Reschke C, Lee W, Liu X, Bandy D, Alexander GE, Thompson PM, Foster NL, Harvey DJ, de Leon MJ, Koeppe RA, Jagust WJ, Weiner MW, Reiman EM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2010 Jun;51(2):654-64. doi: 10.1016/j.neuroimage.2010.02.064. Epub 2010 Mar 2.


Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging.

Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ.

J Alzheimers Dis. 2010;20(3):843-54. doi: 10.3233/JAD-2010-091504. Review.


Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.


Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2011 Jul;32(7):1207-18. doi: 10.1016/j.neurobiolaging.2009.07.002. Epub 2009 Aug 5.

Supplemental Content

Support Center